From Clinical trials to Real World Evidence

Published: 14 Nov 2018

  • Views:

    Views Icon 225
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating


Pradaxa (dabigatran etexilate) is approved in various countries around the world for stroke prevention in patients with atrial fibrillation, primary prevention of venous thromboembolism in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery, and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.